ArticleFrontiers in pharmacology2026
Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence and mortality of renal cell carcinoma (RCC) exhibit marked sex-based differences, suggesting a potential role for androgen signaling in disease progression. Although 5α-reductase inhibitors (5-ARIs) are widely prescribed for benign prostatic conditions, their potential association with survival in patients with RCC remains poorly understood. We evaluated the association between long-term use of 5-ARIs and overall survival in men with RCC. Methods: This population-based retrospective cohort study used data from the Korean National Health Insurance Service database (2007-2020). Men aged ≥40 years with newly diagnosed RCC were included. Long-term 5-ARI use was defined as cumulative prescription of finasteride or dutasteride for ≥365 days prior to diagnosis. Propensity score matching (1:3 ratio) was employed to balance baseline characteristics, including age, year of diagnosis, income, comorbidity burden, and hypertension. The primary outcome was all-cause mortality, analyzed using Cox proportional hazards regression models. Subgroup analyses were stratified by treatment modality and Charlson comorbidity index (CCI). Results: Among 31,927 eligible men, 1,803 5-ARI users were matched with 5,409 non-users (mean age 71.2 years). Long-term 5-ARI use was associated with significantly lower all-cause mortality (hazard ratio [HR]: 0.88; 95% CI: 0.79-0.94; p < 0.001). Although no significant associations were observed in patients undergoing surgery (HR: 0.94; 95% CI: 0.79-1.07) or systemic therapy (HR: 1.15; 95% CI: 0.82-1.55), a distinct survival benefit was evident in the no-surgery/no-systemic therapy group (HR: 0.82; 95% CI: 0.73-0.92; p < 0.001). Within this untreated subgroup, the benefit was most pronounced in patients with low comorbidity (CCI 0-1: HR: 0.78; 95% CI: 0.65-0.91) compared with those with high comorbidity (CCI ≥2: HR: 0.89; 95% CI: 0.76-1.03). Conclusion: Long-term 5-ARI use is associated with improved overall survival in men with RCC, particularly among those with low comorbidity who are managed without active oncological treatment. These findings suggest that androgen modulation may influence RCC progression and support the investigation of 5-ARIs as potential adjunctive agents in selected clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.